RAPT Therapeutics Shares Jump Following Acquisition by GSK

By Connor Hart

Shares of RAPT Therapeutics shot higher after the biopharmaceutical company said it would be acquired by drugmaker GSK for around $2.2 billion.

The stock climbed 64% to $57.41 in premarket trading Tuesday. Through Friday's close, shares have more than tripled over the past year.

Under the terms of the deal, GSK said it will pay $58 apiece for each RAPT share, with a $1.9 billion upfront investment in cash. It is expected to close in the first quarter of 2026, with an estimated aggregate equity value of $2.2 billion.

The British company said the acquisition of RAPT includes ozureprubart, an antibody that is in development for protection against food allergies.

"The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSK's pipeline," said GSK Chief Scientific Officer Tony Wood.

Write to Connor Hart at [e-mail]

(END) Dow Jones Newswires

01-20-26 0634ET